Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
NCT06322238
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pharmacogenomic Drug Interaction
- Side Effect of Drug
- Ineffective Drug Action
- Drug Metabolism, Poor, CYP2D6-Related
- Drug Metabolism, Poor, CYP2C19-Related
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- October 14, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 1
- Mayo Clinic · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.